Top Markets
#1 Black Phoenix Black Phoenix +198.17%
#2 Islamic Coin Islamic Coin +158.03%
#3 Glidr Glidr +84.34%
#4 BasedHype BasedHype +38.64%
#5 Gold Park Gold Park +37.95%
#6 Acurast Acurast +29.31%
#7 Cryptopia Cryptopia +21.79%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
#9 Playnance Playnance +15.62%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +13.63%
Coin of the day
Black Phoenix Black Phoenix
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
InNexus Biotechnology, Inc. InNexus Biotechnology, Inc.

InNexus Biotechnology, Inc.

IXSBF
Classificação em ações #41697
InNexus Biotechnology, Inc. is a development-stage company dedicated to... InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their binding to target antigens, amplifying their effector functions, and endowing them with novel properties. InNexus's development portfolio features several investigational therapies: DXL625: A monoclonal antibody currently in late-stage pre-clinical development, engineered for superior binding kinetics and enhanced effector functions, intended for treating B-cell non-Hodgkin's lymphoma (NHL). DXLr120: A recombinant DXL anti-CD20 antibody also being developed for B-cell NHL. DXL702: A monoclonal antibody targeting metastatic breast cancer. DXL1218: An agent designed to target the epidermal growth factor receptor (EGFR), an antigen frequently overexpressed in metastatic colorectal cancer and squamous cell carcinomas of the head and neck. The company also maintains strategic partnerships with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is based in Vancouver, Canada.
Preço da ação
$0.0001
Última sincronização: 2025-11-07
Valor de mercado
$12.63K
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
CA
Negociar InNexus Biotechnology, Inc. (IXSBF)

Categoria

Healthcare
Receita da InNexus Biotechnology, Inc. (IXSBF)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da InNexus Biotechnology, Inc., a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da InNexus Biotechnology, Inc. de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US